Literature DB >> 16801612

Relapse of diabetes after interruption of chronic administration of anti-tumor necrosis factor-alpha antibody infliximab: a case observation.

Babak Yazdani-Biuki, Thomas Mueller, Hans-Peter Brezinschek, Josef Hermann, Winfried Graninger, Thomas C Wascher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16801612     DOI： 10.2337/dc06-0636

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  11 in total

Review 1.  Immunomodulation at epithelial sites by obesity and metabolic disease.

Authors:  Kitty P Cheung; Kristen R Taylor; Julie M Jameson
Journal:  Immunol Res       Date:  2012-06       Impact factor: 2.829

Review 2.  Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk.

Authors:  Allison B Goldfine; Steven E Shoelson
Journal:  J Clin Invest       Date:  2017-01-03       Impact factor: 14.808

Review 3.  Targeting inflammation in the treatment of type 2 diabetes: time to start.

Authors:  Marc Y Donath
Journal:  Nat Rev Drug Discov       Date:  2014-05-23       Impact factor: 84.694

Review 4.  Inflammation in the Pathophysiology and Therapy of Cardiometabolic Disease.

Authors:  Marc Y Donath; Daniel T Meier; Marianne Böni-Schnetzler
Journal:  Endocr Rev       Date:  2019-08-01       Impact factor: 19.871

Review 5.  Type 2 diabetes as an inflammatory disease.

Authors:  Marc Y Donath; Steven E Shoelson
Journal:  Nat Rev Immunol       Date:  2011-01-14       Impact factor: 53.106

6.  Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients.

Authors:  Luisa Costa; Francesco Caso; Mariangela Atteno; Antonio Del Puente; Md Abud Darda; Paolo Caso; Augusta Ortolan; Ugo Fiocco; Roberta Ramonda; Leonardo Punzi; Raffaele Scarpa
Journal:  Clin Rheumatol       Date:  2014-06       Impact factor: 2.980

Review 7.  Inflammation in obesity, diabetes, and related disorders.

Authors:  Theresa V Rohm; Daniel T Meier; Jerrold M Olefsky; Marc Y Donath
Journal:  Immunity       Date:  2022-01-11       Impact factor: 31.745

Review 8.  Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes.

Authors:  Scott J Pilla; Amy Q Quan; Emily L Germain-Lee; David B Hellmann; Nestoras N Mathioudakis
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

9.  Fast recovery with etanercept in patients affected by polymyalgia rheumatica and decompensated diabetes: a case-series study.

Authors:  Salvatore Corrao; Giovanni Pistone; Rosario Scaglione; Daniela Colomba; Luigi Calvo; Giuseppe Licata
Journal:  Clin Rheumatol       Date:  2008-10-23       Impact factor: 2.980

10.  Suppressive Effects of Insulin on Tumor Necrosis Factor-Dependent Early Osteoarthritic Changes Associated With Obesity and Type 2 Diabetes Mellitus.

Authors:  Daisuke Hamada; Robert Maynard; Eric Schott; Christopher J Drinkwater; John P Ketz; Stephen L Kates; Jennifer H Jonason; Matthew J Hilton; Michael J Zuscik; Robert A Mooney
Journal:  Arthritis Rheumatol       Date:  2016-06       Impact factor: 10.995
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.